The company has yet to generate commercial revenue, with quarterly R&D expenditures consistently averaging approximately $2.7 million as it prioritizes clinical development over profitability.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31.24K | 186.55K | 422.11K | 785.91K | 0 | 236.5K |
| Revenue Growth % | - | - | - | - | - | - | -100% | -83.25% | -55.81% | -46.29% | - | -100% | - |
| Cost of Goods Sold | 367K | 0 | 528K | 546K | 525K | 452.91K | 383.97K | 0 | 0 | 558.87K | 961.47K | 125.42K | 266.44K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | 132.4% | 122.34% | - | 112.66% |
| Gross Profit | -367K | 0 | -528K | -546K | -525K | -452.91K | -383.97K | 31.24K | 186.55K | -136.76K | -175.56K | -125.42K | -29.94K |
| Gross Margin % | - | - | - | - | - | - | - | 100% | 100% | -32.4% | -22.34% | - | -12.66% |
| Gross Profit Growth % | - | 100% | 3.3% | -4% | -15.92% | -17.95% | -1328.99% | -83.25% | 236.41% | 22.1% | -39.97% | -318.89% | - |
| Operating Expenses | 19.64M | 20.9M | 23.3M | 24.69M | 24.41M | 16.44M | 8.75M | 7.71M | 8.04M | 5.97M | 4.48M | 1.16M | 922.72K |
| OpEx % of Revenue | - | - | - | - | - | - | - | 24666.5% | 4310.51% | 1413.49% | 570.5% | - | 390.16% |
| Selling, General & Admin | 10.22M | 10.92M | 11.05M | 11.11M | 14.49M | 10.71M | 4.5M | 4.51M | 6.35M | 5.32M | 4.48M | 1.16M | 922.72K |
| SG&A % of Revenue | - | - | - | - | - | - | - | 14451.07% | 3403.63% | 1259.56% | 570.5% | - | 390.16% |
| Research & Development | 9.54M | 9.98M | 12.25M | 13.58M | 9.91M | 5.73M | 4.25M | 2.21M | 1.24M | 649.74K | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | 7061.17% | 664.02% | 153.93% | - | - | - |
| Other Operating Expenses | -117K | 0 | 0 | 0 | 0 | 0 | 0 | 985.49K | 453.06K | 0 | 0 | 0 | 0 |
| Operating Income | -20.01M | -20.9M | -23.83M | -25.24M | -24.93M | -16.89M | -9.14M | -7.68M | -7.85M | -6.1M | -4.66M | -1.29M | -952.66K |
| Operating Margin % | - | - | - | - | - | - | - | -24566.5% | -4210.51% | -1445.89% | -592.84% | - | -402.82% |
| Operating Income Growth % | - | 12.28% | 5.59% | -1.23% | -47.59% | -84.92% | -19.02% | 2.28% | -28.7% | -30.99% | -261.22% | -35.39% | - |
| EBITDA | -19.64M | -20.41M | -23.3M | -24.69M | -24.41M | -16.44M | -8.75M | -7.28M | -7.72M | -5.96M | -4.51M | -1.16M | -818.53K |
| EBITDA Margin % | - | - | - | - | - | - | - | -23296.89% | -4138.99% | -1412.91% | -573.6% | - | -346.1% |
| EBITDA Growth % | 13.74% | 12.4% | 5.65% | -1.17% | -48.46% | -87.86% | -20.23% | 5.73% | -29.47% | -32.3% | -287.14% | -42.26% | - |
| D&A (Non-Cash Add-back) | 367K | 489K | 528K | 546K | 525K | 452.91K | 383.97K | 396.67K | 133.42K | 139.21K | 151.17K | 125.42K | 134.13K |
| EBIT | -15.25M | -20.9M | -21.82M | -23.52M | -24.67M | -16.53M | -9.14M | -7.62M | -6.18M | -5.87M | -5.53M | -1.29M | -952.66K |
| Net Interest Income | 473K | 692K | 389K | 180K | 161K | 18.71K | 3.74K | 49.91K | -6.86M | -1.92M | -57.89K | -88.52K | -65.49K |
| Interest Income | 495K | 692K | 389K | 180K | 161K | 18.71K | 3.74K | 50.85K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | -3.74K | 933 | 6.86M | 1.92M | 57.89K | 88.52K | 65.49K |
| Other Income/Expense | 1.19M | 1.43M | 2.01M | 1.72M | 263K | 364.68K | -360 | 49.91K | -5.19M | -1.69M | -929.08K | -88.35K | -65.49K |
| Pretax Income | -18.82M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M | -9.14M | -7.63M | -13.04M | -7.79M | -5.59M | -1.38M | -1.02M |
| Pretax Margin % | - | - | - | - | - | - | - | -24406.74% | -6991.46% | -1845.83% | -711.05% | - | -430.51% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.82M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M | -9.14M | -7.63M | -13.04M | -7.79M | -5.89M | -1.6M | -1.4M |
| Net Margin % | - | - | - | - | - | - | - | -24406.74% | -6991.46% | -1845.83% | -749.01% | - | -591.12% |
| Net Income Growth % | 11.78% | 10.76% | 7.22% | 4.67% | -49.26% | -80.92% | -19.8% | 41.54% | -67.4% | -32.36% | -266.99% | -14.74% | - |
| Net Income (Continuing) | -18.82M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M | -9.14M | -7.63M | -13.04M | -7.79M | -5.59M | -1.38M | -1.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.2M | -225.81K | -379.84K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -28.77 | -33.06 | -1555.75 | -2339.75 | -2695.00 | -2327.50 | -9236.50 | -14822.50 | -53495.75 | -26068.00 | -10412.50 | -4483.50 | -5194.00 |
| EPS Growth % | 52.13% | 97.88% | 33.51% | 13.18% | -15.79% | 74.8% | 37.69% | 72.29% | -105.22% | -150.35% | -132.24% | 13.68% | - |
| EPS (Basic) | - | -33.06 | -1555.75 | -2339.75 | -2695.00 | -2327.50 | -9236.50 | -14822.50 | -53495.75 | -26068.00 | -10412.50 | -4483.50 | -5218.50 |
| Diluted Shares Outstanding | 654K | 589K | 13.99K | 10.04K | 9.17K | 7.09K | 1.05K | 515 | 306 | 316 | 358 | 358 | 196 |
| Basic Shares Outstanding | 654K | 589K | 13.99K | 10.04K | 9.17K | 7.09K | 1.05K | 515 | 306 | 316 | 358 | 358 | 195 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Binary Clinical Trial Outcome
As reported in recent financial filings, enVVeno Medical maintains a consistent quarterly R&D expenditure averaging approximately $2.7 million, reflecting the intensive capital requirements of the SAVVE pivotal trial as the company works toward its primary clinical milestones without any offsetting commercial revenue streams to date.
The company's cost structure is dominated by R&D and SG&A, which collectively consume the entirety of available capital. Investors should monitor whether these expenses remain stable or escalate as the company approaches potential commercialization, as the current lack of revenue makes every dollar of operational spend a direct drain on the limited cash runway.
Based on the provided income statement data, the reported net losses are frequently impacted by stock-based compensation, which reached $1.9 million in 2025Q2, suggesting that headline EPS figures may not fully capture the underlying cash-based operational requirements necessary to sustain the firm's clinical development programs.
The volatility in EPS, which has fluctuated significantly across the observed periods, appears largely driven by non-operating adjustments rather than core operational shifts. Analysts should focus on the cash burn rate rather than net income to better understand the company's true financial health and the urgency of its funding needs.
According to the historical income statement data, enVVeno Medical has yet to generate gross profit, with quarterly COGS consistently exceeding revenue, which indicates that the company is currently in a pre-commercial phase where traditional operating leverage metrics are not yet applicable to the business model.
The absence of revenue means that all operating expenses flow directly to the bottom line as losses, preventing any assessment of SG&A efficiency relative to sales. Future analysis must wait for the transition to commercial operations to determine if the company can achieve the necessary scale to cover its fixed cost base.
With reported cash and equivalents of only $3.065 million, the company faces a precarious liquidity position that, based on recent quarterly burn rates, suggests a high probability of near-term dilutive financing requirements to maintain the ongoing SAVVE trial and support the broader transcatheter development program.
The primary risk to the investment thesis is not just clinical failure, but the potential for a liquidity crunch that forces management to raise capital under unfavorable terms. Investors should be wary of the disconnect between the long-term potential of the VenoValve and the immediate, pressing need for cash to survive the regulatory approval process.
Quick answers to the most common questions about buying NVNO stock.
For fiscal year 2025, enVVeno Medical Corporation (NVNO) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.2M in 2014.
enVVeno Medical Corporation (NVNO) reported a net loss of $19.5M for the fiscal year ending 2025.